Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Biogen Inc. (BIIB) came out with quarterly earnings of $5.47 per share, beating the Zacks Consensus Estimate of $3.93 per share. This compares to earnings of $5.28 per share a year ago. These figures ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.

Looking at the chart above, BIIB's low point in its 52 week range is $194.45 per share, with $319.76 as the 52 week high point — that compares with a last trade of $253.71. Find out what 9 other ...

BIIB's PEG compares to its industry's average PEG of 5.21. Over the past 52 weeks, BIIB's PEG has been as high as 2.19 and as low as 0.91, with a median of 1.19.

In February 2025, Biogen Inc. (NASDAQ:BIIB) formed a partnership with Stoke Therapeutics to develop zorevunersen for Dravet ...